EDF1_HUMAN - dbPTM
EDF1_HUMAN - PTM Information in dbPTM
Basic Information of Protein
UniProt ID EDF1_HUMAN
UniProt AC O60869
Protein Name Endothelial differentiation-related factor 1
Gene Name EDF1
Organism Homo sapiens (Human).
Sequence Length 148
Subcellular Localization Cytoplasm. Nucleus. Also nuclear upon binding to NR5A1 and treatment of cells with TPA or forskolin.
Protein Description Transcriptional coactivator stimulating NR5A1 and ligand-dependent NR1H3/LXRA and PPARG transcriptional activities. Enhances the DNA-binding activity of ATF1, ATF2, CREB1 and NR5A1. Regulates nitric oxid synthase activity probably by sequestering calmodulin in the cytoplasm. May function in endothelial cells differentiation, hormone-induced cardiomyocytes hypertrophy and lipid metabolism..
Protein Sequence MAESDWDTVTVLRKKGPTAAQAKSKQAILAAQRRGEDVETSKKWAAGQNKQHSITKNTAKLDRETEELHHDRVTLEVGKVIQQGRQSKGLTQKDLATKINEKPQVIADYESGRAIPNNQVLGKIERAIGLKLRGKDIGKPIEKGPRAK
Overview of Protein Modification Sites with Functional and Structural Information
Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations Modification Substrate Peptides
&
Secondary Structure
ASA (%) Reference Orthologous
Protein Cluster
2Acetylation------MAESDWDTV
------CCCCCCCCC
25.6322223895
4 (in isoform 2)Phosphorylation-34.17-
4Phosphorylation----MAESDWDTVTV
----CCCCCCCCCHH
34.1725159151
8PhosphorylationMAESDWDTVTVLRKK
CCCCCCCCCHHHHHH
17.5222496350
10PhosphorylationESDWDTVTVLRKKGP
CCCCCCCHHHHHHCC
18.8629514088
13MethylationWDTVTVLRKKGPTAA
CCCCHHHHHHCCCHH
34.01-
15UbiquitinationTVTVLRKKGPTAAQA
CCHHHHHHCCCHHHH
64.7824816145
23UbiquitinationGPTAAQAKSKQAILA
CCCHHHHHHHHHHHH
46.2129967540
25UbiquitinationTAAQAKSKQAILAAQ
CHHHHHHHHHHHHHH
42.9432015554
252-HydroxyisobutyrylationTAAQAKSKQAILAAQ
CHHHHHHHHHHHHHH
42.94-
25MethylationTAAQAKSKQAILAAQ
CHHHHHHHHHHHHHH
42.9424129315
25MalonylationTAAQAKSKQAILAAQ
CHHHHHHHHHHHHHH
42.9426320211
40PhosphorylationRRGEDVETSKKWAAG
HCCCCHHHHHHHHCC
45.7726074081
41PhosphorylationRGEDVETSKKWAAGQ
CCCCHHHHHHHHCCC
20.8026074081
42UbiquitinationGEDVETSKKWAAGQN
CCCHHHHHHHHCCCC
60.8133845483
42AcetylationGEDVETSKKWAAGQN
CCCHHHHHHHHCCCC
60.8130588345
502-HydroxyisobutyrylationKWAAGQNKQHSITKN
HHHCCCCCCCCCCCC
41.31-
50UbiquitinationKWAAGQNKQHSITKN
HHHCCCCCCCCCCCC
41.3129967540
50AcetylationKWAAGQNKQHSITKN
HHHCCCCCCCCCCCC
41.3125953088
53 (in isoform 2)Phosphorylation-29.47-
53PhosphorylationAGQNKQHSITKNTAK
CCCCCCCCCCCCCHH
29.4728674151
55PhosphorylationQNKQHSITKNTAKLD
CCCCCCCCCCCHHCC
22.6620068231
58PhosphorylationQHSITKNTAKLDRET
CCCCCCCCHHCCHHH
27.0726074081
60AcetylationSITKNTAKLDRETEE
CCCCCCHHCCHHHHH
49.2125953088
65PhosphorylationTAKLDRETEELHHDR
CHHCCHHHHHHCCCC
35.3428555341
72MethylationTEELHHDRVTLEVGK
HHHHCCCCCHHHHHH
20.97-
74 (in isoform 2)Phosphorylation-20.35-
74PhosphorylationELHHDRVTLEVGKVI
HHCCCCCHHHHHHHH
20.3520068231
79UbiquitinationRVTLEVGKVIQQGRQ
CCHHHHHHHHHHHHH
41.1423000965
79AcetylationRVTLEVGKVIQQGRQ
CCHHHHHHHHHHHHH
41.1426051181
81UbiquitinationTLEVGKVIQQGRQSK
HHHHHHHHHHHHHCC
2.6320972266
84UbiquitinationVGKVIQQGRQSKGLT
HHHHHHHHHHCCCCC
17.1420972266
91PhosphorylationGRQSKGLTQKDLATK
HHHCCCCCHHHHHHH
42.0910816571
91 (in isoform 2)Phosphorylation-42.09-
93MalonylationQSKGLTQKDLATKIN
HCCCCCHHHHHHHHC
49.8526320211
93UbiquitinationQSKGLTQKDLATKIN
HCCCCCHHHHHHHHC
49.8533845483
93AcetylationQSKGLTQKDLATKIN
HCCCCCHHHHHHHHC
49.8523749302
97PhosphorylationLTQKDLATKINEKPQ
CCHHHHHHHHCCCCC
39.4924719451
98AcetylationTQKDLATKINEKPQV
CHHHHHHHHCCCCCE
37.6225953088
982-HydroxyisobutyrylationTQKDLATKINEKPQV
CHHHHHHHHCCCCCE
37.62-
98MalonylationTQKDLATKINEKPQV
CHHHHHHHHCCCCCE
37.6226320211
98UbiquitinationTQKDLATKINEKPQV
CHHHHHHHHCCCCCE
37.6222817900
102 (in isoform 1)Ubiquitination-35.9421890473
1022-HydroxyisobutyrylationLATKINEKPQVIADY
HHHHHCCCCCEEEEC
35.94-
102 (in isoform 2)Ubiquitination-35.9421906983
102UbiquitinationLATKINEKPQVIADY
HHHHHCCCCCEEEEC
35.9422817900
102AcetylationLATKINEKPQVIADY
HHHHHCCCCCEEEEC
35.9426051181
105AcetylationKINEKPQVIADYESG
HHCCCCCEEEECCCC
5.4519608861
105UbiquitinationKINEKPQVIADYESG
HHCCCCCEEEECCCC
5.4532015554
109PhosphorylationKPQVIADYESGRAIP
CCCEEEECCCCCCCC
11.7228796482
111PhosphorylationQVIADYESGRAIPNN
CEEEECCCCCCCCCC
27.6128796482
114UbiquitinationADYESGRAIPNNQVL
EECCCCCCCCCCCHH
25.7224816145
117UbiquitinationESGRAIPNNQVLGKI
CCCCCCCCCCHHHHH
45.5124816145
118UbiquitinationSGRAIPNNQVLGKIE
CCCCCCCCCHHHHHH
28.1623000965
121UbiquitinationAIPNNQVLGKIERAI
CCCCCCHHHHHHHHH
4.1023000965
122UbiquitinationIPNNQVLGKIERAIG
CCCCCHHHHHHHHHC
30.0023000965
123AcetylationPNNQVLGKIERAIGL
CCCCHHHHHHHHHCC
36.9123954790
123UbiquitinationPNNQVLGKIERAIGL
CCCCHHHHHHHHHCC
36.9132015554
123 (in isoform 2)Acetylation-36.91-
125UbiquitinationNQVLGKIERAIGLKL
CCHHHHHHHHHCCEE
39.2723000965
127UbiquitinationVLGKIERAIGLKLRG
HHHHHHHHHCCEECC
6.3423000965
130UbiquitinationKIERAIGLKLRGKDI
HHHHHHCCEECCCCC
3.7423000965
131AcetylationIERAIGLKLRGKDIG
HHHHHCCEECCCCCC
30.8125953088
131UbiquitinationIERAIGLKLRGKDIG
HHHHHCCEECCCCCC
30.81-
131MalonylationIERAIGLKLRGKDIG
HHHHHCCEECCCCCC
30.8126320211
135UbiquitinationIGLKLRGKDIGKPIE
HCCEECCCCCCCCCC
39.4724816145
135AcetylationIGLKLRGKDIGKPIE
HCCEECCCCCCCCCC
39.4726051181
139UbiquitinationLRGKDIGKPIEKGPR
ECCCCCCCCCCCCCC
43.0623000965
143 (in isoform 1)Ubiquitination-74.9621890473
143AcetylationDIGKPIEKGPRAK--
CCCCCCCCCCCCC--
74.9625953088
143UbiquitinationDIGKPIEKGPRAK--
CCCCCCCCCCCCC--
74.9623000965
148UbiquitinationIEKGPRAK-------
CCCCCCCC-------
63.2523000965

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)
Modified Location Modified Residue Modification Type of Upstream Proteins Gene Name of Upstream Proteins UniProt AC of Upstream Proteins Sources

Oops, there are no upstream regulatory protein records of EDF1_HUMAN !!

Functions of PTM Sites
Modified Location Modified Residue Modification Function Reference

Oops, there are no descriptions of PTM sites of EDF1_HUMAN !!

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Modified Location Modification Variant Position
(Distance <= 10)
Residue Change SAP Related Disease Reference

Oops, there are no SNP-PTM records of EDF1_HUMAN !!

Protein-Protein Interaction
Interacting Protein Gene Name Interaction Type PPI Reference Domain-Domain Interactions
NR5A2_HUMANNR5A2physical
12040021
NR1H3_HUMANNR1H3physical
12040021
PPARG_HUMANPPARGphysical
12040021
RXRA_HUMANRXRAphysical
12040021
TBP_HUMANTBPphysical
12040021
TBP_HUMANTBPphysical
10816571
TBP_HUMANTBPphysical
10567391
STF1_HUMANNR5A1physical
10567391
NRL_HUMANNRLphysical
16880509
JUN_HUMANJUNphysical
16880509
CEBPA_HUMANCEBPAphysical
16880509
IDH3G_HUMANIDH3Gphysical
22939629
DNJB1_HUMANDNAJB1physical
26344197
HNRPF_HUMANHNRNPFphysical
26344197

Drug and Disease Associations
Kegg Disease
There are no disease associations of PTM sites.
OMIM Disease
There are no disease associations of PTM sites.
Kegg Drug
There are no disease associations of PTM sites.
DrugBank
There are no disease associations of PTM sites.
Regulatory Network of EDF1_HUMAN

loading...

Related Literatures of Post-Translational Modification
Acetylation
ReferencePubMed
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT SER-4, AND MASS SPECTROMETRY.
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions.";
Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.;
Science 325:834-840(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-123, AND MASS SPECTROMETRY.
Phosphorylation
ReferencePubMed
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGESCALE ANALYSIS] AT SER-4, AND MASS SPECTROMETRY.

TOP